In Vitro Diagnostics Market by Product and Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Infectious Disease), End User (Hospitals, Clinics) - Forecast to 2027
In Vitro Diagnostics Market by Product and Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Infectious Disease), End User (Hospitals, Clinics) - Forecast to 2027
Abstract
The in vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%. The growing adoption of point-of-care devices and rapid tests for early disease diagnosis, and the rising government initiatives & funding for preventive cure with early diagnosis and treatment drive growth in the market.
The reagents & kits segment accounted for the largest share of the market
On the basis of product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software. The reagents & kits segment accounted for the largest share of the IVD market in 2021. The recurring use of reagents in various handheld and complex laboratory IVD instruments for disease testing and monitoring is a major factor driving the growth of this segment.
The immunoassay/immunochemistry segment accounted for the largest share of the IVD technology market
Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies. The immunoassay/immunochemistry segment accounted for the largest share of the IVD technologies market in 2021. Immunoassays are mostly preferred for immunodiagnostic techniques over other diagnostic methods due to the ability of these tests to provide rapid results, and simplistic sample preparation needs with minimal human intervention.
The infectious disease segment accounted for the largest share of the IVD market
On the basis of application, the IVD market is segmented based on application into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology, and other applications. In 2021, the infectious diseases segment accounted for the largest share of the IVD market. The large share of this segment can be attributed to the growing need for effective diagnostic tools for the rising prevalence of multi-drug-resistant infectious diseases.
Point-of care testing to register the highest growth during the forecast period
Based on end users, the IVD market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. Point-of-care segment to register the highest CAGR during the forecast period. The growth in this market is attributed to the increasing need for testing and early disease diagnosis of diseases in remote locations. Moreover, the technological advancements in the point-of- care testing, make them more reliable and accurate driving the growth of this market.
APAC is expected to grow at the highest CAGR during the forecast period
The IVD market in the Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region can be attributed to the rising demand for better healthcare services, rapid development in the healthcare infrastructure of emerging markets, and the growing government initiatives on preventive care methods.
A breakdown of the primary participants for the in vitro diagnostics market referred to for this report is provided below:
•By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
•By Designation: C-level–35%, Director Level–25%, and Others–40%
•By Region: North America–45%, Europe–30%, Asia Pacific–20%, Latin America – 3%, Middle East & Africa – 2%
The prominent players in the global in vitro diagnostics market are Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc (US), Becton, Dickinson and Company (BD, US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Quidel Corporation (US), bioMérieux SA (France), Agilent Technologies, Inc. (US), Chembio Diagnostics, Inc. (US), DiaSorin S.p.A (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Devyser (Sweden), PerkinElmer Inc. (US), Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), and Caris Life Sciences Inc. (US).
Research Coverage
The report analyzes the market for various in vitro diagnostics products & services and their adoption pattern. It aims at estimating the market size and future growth potential of the in vitro diagnostics market and different segments such as by technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, services, and recent developments.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers:
•Market Penetration: Comprehensive information on the service portfolios offered by the top players in the global in vitro diagnostics market.
•Service Development/Innovation: Detailed insights on the upcoming trend, and service launches in the global in vitro diagnostics market.
•Market Development: Comprehensive information on the lucrative emerging regions by product & services, technology, application, end users, and region.
•Market Diversification: Exhaustive information about new products & services, growing geographies, and recent developments in the global in vitro diagnostics market.
•Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global in vitro diagnostics market.
Content
Table of Contents
1INTRODUCTION43
1.1STUDY OBJECTIVES43
1.2MARKET DEFINITION43
1.2.1INCLUSIONS & EXCLUSIONS44
1.2.2MARKET SEGMENTATION45
FIGURE 1IN VITRO DIAGNOSTICS MARKET SEGMENTATION45
1.2.3YEARS CONSIDERED46
1.3CURRENCY CONSIDERED46
TABLE 1EXCHANGE RATES UTILIZED FOR CONVERSION TO USD46
1.4STAKEHOLDERS47
1.5SUMMARY OF CHANGES47
2RESEARCH METHODOLOGY48
2.1RESEARCH APPROACH48
FIGURE 2RESEARCH DESIGN48
2.1.1SECONDARY RESEARCH48
2.1.1.1Key data from secondary sources49
2.1.2PRIMARY RESEARCH50
2.1.2.1Primary sources50
2.1.2.2Key data from primary sources51
2.1.2.3Key industry insights51
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS52
FIGURE 4BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION52
FIGURE 5BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION53
2.2MARKET SIZE ESTIMATION53
FIGURE 6MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021)54
FIGURE 7REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2021)54
FIGURE 8SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS MARKET (2021)55
FIGURE 9IVD MARKET: TOP-DOWN APPROACH56
FIGURE 10CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE
IVD INDUSTRY (2022–2027)57
FIGURE 11CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET57
2.3DATA TRIANGULATION APPROACH59
FIGURE 12DATA TRIANGULATION METHODOLOGY59
2.4MARKET SHARE ESTIMATION60
2.5STUDY ASSUMPTIONS60
2.6LIMITATIONS60
2.6.1METHODOLOGY-RELATED LIMITATIONS60
2.6.2SCOPE-RELATED LIMITATIONS60
2.7RISK ASSESSMENT61
TABLE 2RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET61
3EXECUTIVE SUMMARY62
FIGURE 13IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION)62
FIGURE 14IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022 VS. 2027 (USD MILLION)63
FIGURE 15IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION)63
FIGURE 16IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION)64
FIGURE 17GEOGRAPHIC SNAPSHOT OF IVD MARKET65
4PREMIUM INSIGHTS66
4.1IN VITRO DIAGNOSTICS MARKET OVERVIEW66
FIGURE 18RISING INCIDENCE OF INFECTIOUS DISEASES AND GROWING ADOPTION OF TECHNOLOGICALLY ADVANCED ANALYZERS TO DRIVE MARKET66
4.2ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021)67
FIGURE 19REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 202167
4.3IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES68
FIGURE 20CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD68
4.4IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX68
FIGURE 21ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD68
4.5IN VITRO DIAGNOSTICS MARKET: EMERGING VS. DEVELOPED MARKETS69
FIGURE 22EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD69
5MARKET OVERVIEW70
5.1INTRODUCTION70
5.2MARKET DYNAMICS70
FIGURE 23IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES70
5.2.1DRIVERS71
5.2.1.1Increasing geriatric population and subsequent rise in chronic & infectious diseases71
TABLE 3ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019–2050)71
5.2.1.2Gradual shift from centralized testing to point-of-care testing72
5.2.1.3Growing awareness of early disease diagnosis in emerging economies72
5.2.1.4Emergence of rapid PoC technologies and rising adoption of automated analyzers73
TABLE 4IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES (2020−2022)73
5.2.2RESTRAINTS74
5.2.2.1Unfavorable reimbursement scenario74
5.2.3OPPORTUNITIES74
5.2.3.1Introduction of disease-specific biomarkers and tests74
TABLE 5APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE75
5.2.3.2Growing significance of companion diagnostics75
5.2.3.3Growth opportunities in emerging markets76
TABLE 6RECENT DEVELOPMENTS IN EMERGING MARKETS76
5.2.4CHALLENGES77
5.2.4.1Stringent regulatory & legal guidelines77
FIGURE 24IVDR: KEY AREAS OF IMPACT77
5.2.4.2Operational barriers78
TABLE 7IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES78
5.3INDUSTRY TRENDS79
5.3.1AUTOMATION OF CLINICAL LABORATORY TECHNIQUES79
5.3.2MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING79
5.3.3RISING NUMBER OF REAGENT RENTAL AGREEMENTS80
5.3.4REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS80
FIGURE 25REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS80
5.4PORTER’S FIVE FORCES ANALYSIS81
TABLE 8PORTER’S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET81
5.4.1INTENSITY OF COMPETITIVE RIVALRY81
5.4.2BARGAINING POWER OF SUPPLIERS81
5.4.3BARGAINING POWER OF BUYERS81
5.4.4THREAT OF NEW ENTRANTS81
5.4.5THREAT FROM SUBSTITUTES82
5.5REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS82
TABLE 9LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS82
5.6REGULATORY ANALYSIS83
5.6.1NORTH AMERICA83
5.6.1.1US83
TABLE 10US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES83
FIGURE 26US: REGULATORY PROCESS FOR IVD DEVICES84
5.6.1.2Canada85
FIGURE 27CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA85
5.6.2EUROPE85
TABLE 11EUROPE: CLASSIFICATION OF IVD DEVICES86
FIGURE 28EUROPE: IVDR TIMELINE86
5.6.3ASIA PACIFIC87
5.6.3.1Japan87
FIGURE 29REGULATORY PROCESS FOR IVD DEVICES IN JAPAN87
TABLE 12JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN88
TABLE 13JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS88
5.6.3.2China88
TABLE 14CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS88
5.6.3.3India89
FIGURE 30INDIA: REGULATORY PROCESS FOR IVD DEVICES89
5.6.3.4South Korea89
TABLE 15SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS89
5.6.3.5Indonesia90
TABLE 16INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES90
5.6.4RUSSIA90
TABLE 17RUSSIA: CLASSIFICATION OF IVD DEVICES91
5.6.5MIDDLE EAST & AFRICA91
5.6.5.1Saudi Arabia91
TABLE 18SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS91
5.6.5.2Africa91
5.6.6LATIN AMERICA92
5.6.6.1Mexico92
FIGURE 31MEXICO: REGULATORY PROCESS FOR IVD DEVICES92
TABLE 19MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS93
5.6.6.2Brazil93
5.7KEY CONFERENCES & EVENTS IN 202394
TABLE 20IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS94
5.8PATENT ANALYSIS95
5.8.1INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS95
FIGURE 32TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011–DECEMBER 2022)95
FIGURE 33TOP APPLICANT JURISDICTIONS FOR IVD PATENTS
(JANUARY 20211-DECEMBER 2022)96
5.8.2PATENT PUBLICATION TRENDS FOR IN VITRO DIAGNOSTICS MARKET96
FIGURE 34PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET
(JANUARY 2011–DECEMBER 2022)96
TABLE 21LIST OF PATENTS/PATENT APPLICATIONS IN IVD MARKET, 2021–202297
5.9TRADE ANALYSIS98
5.9.1TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS98
TABLE 22IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (USD MILLION)98
TABLE 23EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (TONS)98
5.10ECOSYSTEM ANALYSIS98
FIGURE 35ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET99
5.10.1IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM99
5.11VALUE CHAIN ANALYSIS100
FIGURE 36VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET100
5.12SUPPLY CHAIN ANALYSIS101
FIGURE 37SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET101
5.13PRICING ANALYSIS102
5.13.1INDICATIVE AVERAGE SELLING PRICE (USD) REGION-WISE: REAGENTS & KITS102
5.13.2AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS102
5.13.3AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS102
5.13.4AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS103
5.14TECHNOLOGY ANALYSIS104
5.14.1KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET104
5.14.2ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET105
5.15CASE STUDY106
FIGURE 38CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA106
5.16KEY STAKEHOLDERS & BUYING CRITERIA107
5.16.1KEY STAKEHOLDERS IN BUYING PROCESS107
FIGURE 39INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS107
TABLE 24INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS (%)107
5.16.2BUYING CRITERIA108
FIGURE 40KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS108
TABLE 25KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS108
5.17IMPACT OF RECESSION ON IVD MARKET (2021–2024)108
5.18IMPACT OF IN VITRO DIAGNOSTIC REGULATIONS (IVDR) ON LABORATORY TESTING109
6IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE111
6.1INTRODUCTION112
TABLE 26IN VITRO DIAGNOSTIC MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)112
6.2REAGENTS & KITS112
6.2.1GROWING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET112
TABLE 27IVD MARKET FOR REAGENTS & KITS, BY COUNTRY,
2020–2027 (USD MILLION)114
6.3INSTRUMENTS114
TABLE 28KEY INSTRUMENTS AVAILABLE IN IVD MARKET115
TABLE 29IVD MARKET FOR INSTRUMENTS, BY TYPE, 2020–2027 (USD MILLION)116
TABLE 30IVD MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)116
6.3.1FULLY AUTOMATED INSTRUMENTS117
6.3.1.1Rising availability of technologically advanced analyzers to drive market117
TABLE 31IVD MARKET FOR FULLY AUTOMATED INSTRUMENTS, BY COUNTRY,
2020–2027 (USD MILLION)118
6.3.2SEMI-AUTOMATED INSTRUMENTS118
6.3.2.1Compact design and cost-effectiveness over automated analyzers to support market growth118
TABLE 32IVD MARKET FOR SEMIAUTOMATED INSTRUMENTS, BY COUNTRY,
2020–2027 (USD MILLION)119
6.3.3OTHER INSTRUMENTS119
TABLE 33IVD MARKET FOR OTHER INSTRUMENTS, BY COUNTRY,
2020–2027 (USD MILLION)120
6.4DATA MANAGEMENT SOFTWARE120
6.4.1GROWING ADOPTION OF AUTOMATED ANALYZERS AND RISING NEED FOR EFFECTIVE DATA MANAGEMENT TO DRIVE MARKET120
TABLE 34KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN IVD MARKET121
TABLE 35IVD MARKET FOR DATA MANAGEMENT SOFTWARE, BY COUNTRY,
2020–2027 (USD MILLION)122
6.5SERVICES122
6.5.1RISING NEED TO ENSURE EFFECTIVE UTILISATION OF IVD PRODUCTS TO SUPPORT MARKET GROWTH122
TABLE 36IVD MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)123
7IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY124
7.1INTRODUCTION125
TABLE 37IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)125
7.2IMMUNOASSAY/IMMUNOCHEMISTRY125
TABLE 38KEY IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE IN IVD MARKET126
TABLE 39IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY,
BY TYPE, 2020–2027 (USD MILLION)127
TABLE 40IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY,
BY COUNTRY, 2020–2027 (USD MILLION)127
7.2.1ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)128
TABLE 41KEY ELISA ANALYZERS AVAILABLE IN IVD MARKET128
TABLE 42IVD MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)129
TABLE 43IVD MARKET FOR ELISA, BY COUNTRY, 2020–2027 (USD MILLION)130
7.2.1.1Chemiluminescence Immunoassays130
7.2.1.1.1Rising technological advancements and continuous product innovations to drive segment growth130
TABLE 44KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET131
TABLE 45IVD MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)132
7.2.1.2Fluorescence Immunoassays132
7.2.1.2.1Rising demand for low-cost fluorescent dyes to drive segment growth132
TABLE 46KEY FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET133
TABLE 47IVD MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY,
2020–2027 (USD MILLION)134
7.2.1.3Colorimetric Immunoassays134
7.2.1.3.1High specificity and easy coagulation to antibodies to drive segment growth134
TABLE 48KEY COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET135
TABLE 49IVD MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY,
2020–2027 (USD MILLION)135
7.2.2RADIOIMMUNOASSAYS136
7.2.2.1Usage of RIAs in cancer detection, blood screening, and drug discovery to drive market136
TABLE 50IVD MARKET FOR RADIOIMMUNOASSAYS, BY COUNTRY,
2020–2027 (USD MILLION)136
7.2.3RAPID TESTS137
7.2.3.1Rising usage of rapid tests for emergency care to drive market137
TABLE 51KEY RAPID TESTS AVAILABLE IN IVD MARKET137
TABLE 52IVD MARKET FOR RAPID TESTS, BY COUNTRY, 2020–2027 (USD MILLION)138
7.2.4WESTERN BLOTTING138
7.2.4.1Widely accepted technique for result validation to support market growth138
TABLE 53KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN IVD MARKET139
TABLE 54IVD MARKET FOR WESTERN BLOTTING, BY COUNTRY,
2020–2027 (USD MILLION)139
7.2.5ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)140
7.2.5.1High sensitivity and adaptability of technology to fuel market adoption140
TABLE 55IVD MARKET FOR ELISPOT ASSAYS, BY COUNTRY,
2020–2027 (USD MILLION)140
7.3CLINICAL CHEMISTRY141
TABLE 56CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES141
TABLE 57CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES142
TABLE 58KEY BLOOD GAS ANALYZERS AVAILABLE IN IVD MARKET143
TABLE 59IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE,
2020–2027 (USD MILLION)144
TABLE 60CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)144
7.3.1BASIC METABOLIC PANELS145
7.3.1.1Set of blood tests performed to ascertain common acute conditions145
TABLE 61IVD MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY,
2020–2027 (USD MILLION)145
7.3.2LIVER PANELS146
7.3.2.1Panels used to identify and monitor liver diseases & injuries146
TABLE 62IVD MARKET FOR LIVER PANELS, BY COUNTRY, 2020–2027 (USD MILLION)146
7.3.3RENAL PROFILES147
7.3.3.1Panels used to monitor cytokines & chemokines in urine147
TABLE 63IVD MARKET FOR RENAL PROFILES, BY COUNTRY,
2020–2027 (USD MILLION)147
7.3.4LIPID PROFILES148
7.3.4.1Lipid panel testing determines total cholesterol and risk status for CVD148
TABLE 64IVD MARKET FOR LIPID PROFILES, BY COUNTRY,
2020–2027 (USD MILLION)148
7.3.5THYROID FUNCTION PANELS149
7.3.5.1Tests performed to determine TSH and thyroglobulin149
TABLE 65IVD MARKET FOR THYROID FUNCTION PANELS, BY COUNTRY,
2020–2027 (USD MILLION)149
7.3.6ELECTROLYTE PANELS150
7.3.6.1Prescribed for symptoms such as edema, nausea, and cardiac arrhythmia150
TABLE 66IVD MARKET FOR ELECTROLYTE PANELS, BY COUNTRY,
2020–2027 (USD MILLION)150
7.3.7SPECIALTY CHEMICAL TESTS151
7.3.7.1Test profile includes immunosuppressant drug monitoring and drugs of abuse151
TABLE 67IVD MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY,
2020–2027 (USD MILLION)151
7.4MOLECULAR DIAGNOSTICS152
TABLE 68KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN IVD MARKET152
TABLE 69IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE,
2020–2027 (USD MILLION)153
TABLE 70IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY,
2020–2027 (USD MILLION)154
7.4.1POLYMERASE CHAIN REACTION (PCR)154
7.4.1.1Rising prevalence of infectious & viral diseases to drive market154
TABLE 71KEY PCR INSTRUMENTS AVAILABLE IN IVD MARKET155
TABLE 72IVD MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY,
2020–2027 (USD MILLION)156
7.4.2ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)156
7.4.2.1Growing popularity of INAAT and NAAT for infectious disease diagnostics to support market growth156
TABLE 73IVD MARKET FOR INAAT, BY COUNTRY, 2020–2027 (USD MILLION)157
7.4.3HYBRIDIZATION157
7.4.3.1Advanced hybridization & automation of data collection techniques to support market growth157
TABLE 74IVD MARKET FOR HYBRIDIZATION, BY COUNTRY, 2020–2027 (USD MILLION)158
7.4.4DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)158
7.4.4.1Rising demand for personalized medicine to support market growth158
TABLE 75KEY NGS INSTRUMENTS AVAILABLE IN IVD MARKET159
TABLE 76IVD MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY,
2020–2027 (USD MILLION)160
7.4.5MICROARRAYS160
7.4.5.1High throughput & resolution capabilities to drive market for protein expression profiling160
TABLE 77IVD MARKET FOR MICROARRAYS, BY COUNTRY, 2020–2027 (USD MILLION)161
7.4.6OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES162
TABLE 78IVD MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES,
BY COUNTRY, 2020–2027 (USD MILLION)162
7.5HEMATOLOGY163
7.5.1INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS TO DRIVE MARKET163
TABLE 79KEY HEMATOLOGY ANALYZERS AVAILABLE IN IVD MARKET163
TABLE 80IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)164
7.6MICROBIOLOGY165
7.6.1RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET165
TABLE 81KEY MICROBIOLOGY INSTRUMENTS AVAILABLE IN IVD MARKET165
TABLE 82IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)166
7.7COAGULATION & HEMOSTASIS167
7.7.1GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET167
TABLE 83KEY COAGULATION ANALYZERS AVAILABLE IN IVD MARKET167
TABLE 84KEY POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE IN IVD MARKET168
TABLE 85IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY,
2020–2027 (USD MILLION)169
7.8URINALYSIS169
7.8.1RISING PREVALENCE OF KIDNEY DISORDERS AND UTIS TO DRIVE MARKET169
TABLE 86KEY URINALYSIS INSTRUMENTS AVAILABLE IN IVD MARKET170
TABLE 87IVD MARKET FOR URINALYSIS, BY COUNTRY, 2020–2027 (USD MILLION)171
7.9OTHER TECHNOLOGIES171
TABLE 88KEY BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN IVD MARKET172
TABLE 89TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE IN IVD MARKET172
TABLE 90IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,
2020–2027 (USD MILLION)173
8IN VITRO DIAGNOSTICS MARKET, BY APPLICATION174
8.1INTRODUCTION175
TABLE 91IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)175
8.2INFECTIOUS DISEASES175
8.2.1INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE ADOPTION OF IVD PRODUCTS175
TABLE 92IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2020–2027 (USD MILLION)176
8.3DIABETES177
8.3.1RISING PREVALENCE OF DIABETES TO DRIVE ADOPTION OF GLUCOSE MONITORING DEVICES177
TABLE 93COUNTRIES WITH A DIABETIC PATIENT POPULATION,
2021 VS. 2045 (MILLION)177
TABLE 94IVD MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION)178
8.4ONCOLOGY178
8.4.1RISING INITIATIVES FOR EARLY DETECTION OF CANCER TO DRIVE MARKET178
TABLE 95IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)179
8.5CARDIOLOGY180
8.5.1INCREASING USE OF IMMUNOASSAYS IN DETECTION OF CVD TO DRIVE MARKET180
TABLE 96IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)181
8.6DRUG TESTING/PHARMACOGENOMICS181
8.6.1INCREASING USE OF TOXICOLOGY TESTING FOR ILLICIT DRUGS TO DRIVE MARKET181
TABLE 97IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY, 2020–2027 (USD MILLION)182
8.7HIV/AIDS182
8.7.1INCREASING USAGE OF REAL-TIME PCR TESTS FOR HIV DETECTION TO DRIVE MARKET182
TABLE 98IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2020–2027 (USD MILLION)183
8.8AUTOIMMUNE DISEASES183
8.8.1GROWING DEMAND FOR PORTABLE POC DIAGNOSTIC DEVICES TO DRIVE MARKET183
TABLE 99IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY,
2020–2027 (USD MILLION)184
8.9NEPHROLOGY185
8.9.1INCREASING USE OF BIOMARKERS FOR CKD TO SUPPORT MARKET GROWTH185
TABLE 100IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)186
8.10OTHER APPLICATIONS186
TABLE 101IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION)187
9IN VITRO DIAGNOSTICS MARKET, BY END USER188
9.1INTRODUCTION189
TABLE 102IN-VITRO DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)189
9.2HOSPITAL LABORATORIES189
9.2.1RISING NUMBER OF HOSPITALIZATIONS DUE TO INCREASING INFECTIOUS DISEASES TO DRIVE MARKET189
TABLE 103IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY,
2020–2027 (USD MILLION)191
9.3CLINICAL LABORATORIES191
TABLE 104IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)192
TABLE 105IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)192
9.3.1LARGE REFERENCE LABORATORIES193
9.3.1.1Capability to conduct specific tests such as LDTs with advanced diagnostic tools to drive segment growth193
TABLE 106LARGE REFERENCE LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)193
9.3.2MEDIUM-SIZED LABORATORIES194
9.3.2.1Increasing adoption of automated instruments to drive growth of this segment194
TABLE 107MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)194
9.3.3SMALL LABORATORIES195
9.3.3.1Adoption of point-of-care devices to support segment growth195
TABLE 108SMALL LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)195
9.4POINT-OF-CARE TESTING CENTERS196
9.4.1RISING DEMAND FOR RAPID TESTING AND AVAILABILITY OF INNOVATIVE POINT-OF-CARE IVD PRODUCTS TO DRIVE MARKET196
TABLE 109IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2020–2027 (USD MILLION)197
9.5PATIENTS197
9.5.1USE OF CONVENIENT SELF-TEST KITS TO DRIVE MARKET197
TABLE 110IVD MARKET FOR PATIENTS, BY COUNTRY, 2020–2027 (USD MILLION)198
9.6ACADEMIC INSTITUTES199
9.6.1RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH199
TABLE 111IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)199
9.7OTHER END USERS200
TABLE 112IVD MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)201
10IN VITRO DIAGNOSTICS MARKET, BY REGION202
10.1INTRODUCTION203
FIGURE 41IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT (2021)203
TABLE 113IN VITRO DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION)204
10.2NORTH AMERICA204
FIGURE 42NORTH AMERICA: IVD MARKET SNAPSHOT205
TABLE 114NORTH AMERICA: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)205
TABLE 115NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)206
TABLE 116NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)206
TABLE 117NORTH AMERICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)207
TABLE 118NORTH AMERICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)207
TABLE 119NORTH AMERICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)208
TABLE 120NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)208
10.2.1US208
10.2.1.1Established reimbursement framework and favorable policies for IVD providers to drive market208
TABLE 121US: MACROECONOMIC INDICATORS210
TABLE 122US: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)210
TABLE 123US: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)210
TABLE 124US: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)211
TABLE 125US: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)211
TABLE 126US: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)212
TABLE 127US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)212
10.2.2CANADA212
10.2.2.1Rising government initiatives & funding for early disease diagnosis to drive market212
TABLE 128CANADA: ESTIMATED PREVALENCE OF DIABETES213
TABLE 129CANADA: MACROECONOMIC INDICATORS214
TABLE 130CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)214
TABLE 131CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)215
TABLE 132CANADA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)215
TABLE 133CANADA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)216
TABLE 134CANADA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)216
TABLE 135CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)217
10.3EUROPE217
TABLE 136EUROPE: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)218
TABLE 137EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)218
TABLE 138EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)218
TABLE 139EUROPE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)219
TABLE 140EUROPE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)219
TABLE 141EUROPE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)220
TABLE 142EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)220
10.3.1GERMANY220
10.3.1.1Growing investments in clinical diagnostics research to drive market220
TABLE 143GERMANY: MACROECONOMIC INDICATORS221
TABLE 144GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)221
TABLE 145GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)222
TABLE 146GERMANY: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)222
TABLE 147GERMANY: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)223
TABLE 148GERMANY: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)223
TABLE 149GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)224
10.3.2FRANCE224
10.3.2.1High healthcare expenditure and rising investments in genomic medicine to drive market224
TABLE 150FRANCE: MACROECONOMIC INDICATORS225
TABLE 151FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)225
TABLE 152FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)225
TABLE 153FRANCE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)226
TABLE 154FRANCE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)226
TABLE 155FRANCE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)227
TABLE 156FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)227
10.3.3UK227
10.3.3.1Rising adoption of genome-based testing and increasing accessibility to IVD tests to drive market227
TABLE 157UK: MACROECONOMIC INDICATORS228
TABLE 158UK: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)229
TABLE 159UK: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)229
TABLE 160UK: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)230
TABLE 161UK: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)230
TABLE 162UK: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)231
TABLE 163UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)231
10.3.4ITALY231
10.3.4.1Growing geriatric population and subsequent rise in chronic conditions to support market growth231
TABLE 164ITALY: MACROECONOMIC INDICATORS232
TABLE 165ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)233
TABLE 166ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)233
TABLE 167ITALY: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)233
TABLE 168ITALY: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)234
TABLE 169ITALY: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)234
TABLE 170ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)235
10.3.5SPAIN235
10.3.5.1Rising adoption of technologically advanced immunoassay systems to drive market235
TABLE 171SPAIN: MACROECONOMIC INDICATORS236
TABLE 172SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)236
TABLE 173SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)236
TABLE 174SPAIN: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)237
TABLE 175SPAIN: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)237
TABLE 176SPAIN: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)238
TABLE 177SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)238
10.3.6RUSSIA238
10.3.6.1Rising incidence of non-communicable diseases and government support for medical services to support market growth238
TABLE 178RUSSIA: MACROECONOMIC INDICATORS239
TABLE 179RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)239
TABLE 180RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)240
TABLE 181RUSSIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)240
TABLE 182RUSSIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)241
TABLE 183RUSSIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)241
TABLE 184RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)242
10.3.7REST OF EUROPE242
TABLE 185REST OF EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)242
TABLE 186REST OF EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)243
TABLE 187REST OF EUROPE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)243
TABLE 188REST OF EUROPE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)244
TABLE 189REST OF EUROPE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)244
TABLE 190REST OF EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)245
10.4ASIA PACIFIC245
FIGURE 43ASIA PACIFIC: IVD MARKET SNAPSHOT246
TABLE 191ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)247
TABLE 192ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)247
TABLE 193ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)247
TABLE 194ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)248
TABLE 195ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)248
TABLE 196ASIA PACIFIC: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)249
TABLE 197ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)249
10.4.1JAPAN249
10.4.1.1Universal healthcare reimbursement policy and research investments for immunoassays to support market growth249
TABLE 198JAPAN: MACROECONOMIC INDICATORS250
TABLE 199JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)251
TABLE 200JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)251
TABLE 201JAPAN: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION))251
TABLE 202JAPAN: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)252
TABLE 203JAPAN: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)252
TABLE 204JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)253
10.4.2CHINA253
10.4.2.1Increasing awareness of preventive care to drive market for advanced & rapid testing platforms253
TABLE 205CHINA: MACROECONOMIC INDICATORS254
TABLE 206CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)254
TABLE 207CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)254
TABLE 208CHINA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)255
TABLE 209CHINA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)255
TABLE 210CHINA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)256
TABLE 211CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)256
10.4.3INDIA256
10.4.3.1Rising incidence of diabetes and cancer to fuel market growth for IVD products256
TABLE 212INDIA: MACROECONOMIC INDICATORS257
TABLE 213INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)258
TABLE 214INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)258
TABLE 215INDIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)258
TABLE 216INDIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)259
TABLE 217INDIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)259
TABLE 218INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)260
10.4.4SOUTH KOREA260
10.4.4.1Rising healthcare spending for innovative IVD technologies to support market growth260
TABLE 219SOUTH KOREA: MACROECONOMIC INDICATORS261
TABLE 220SOUTH KOREA: IVD MA
The reagents & kits segment accounted for the largest share of the market
On the basis of product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software. The reagents & kits segment accounted for the largest share of the IVD market in 2021. The recurring use of reagents in various handheld and complex laboratory IVD instruments for disease testing and monitoring is a major factor driving the growth of this segment.
The immunoassay/immunochemistry segment accounted for the largest share of the IVD technology market
Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies. The immunoassay/immunochemistry segment accounted for the largest share of the IVD technologies market in 2021. Immunoassays are mostly preferred for immunodiagnostic techniques over other diagnostic methods due to the ability of these tests to provide rapid results, and simplistic sample preparation needs with minimal human intervention.
The infectious disease segment accounted for the largest share of the IVD market
On the basis of application, the IVD market is segmented based on application into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology, and other applications. In 2021, the infectious diseases segment accounted for the largest share of the IVD market. The large share of this segment can be attributed to the growing need for effective diagnostic tools for the rising prevalence of multi-drug-resistant infectious diseases.
Point-of care testing to register the highest growth during the forecast period
Based on end users, the IVD market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. Point-of-care segment to register the highest CAGR during the forecast period. The growth in this market is attributed to the increasing need for testing and early disease diagnosis of diseases in remote locations. Moreover, the technological advancements in the point-of- care testing, make them more reliable and accurate driving the growth of this market.
APAC is expected to grow at the highest CAGR during the forecast period
The IVD market in the Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region can be attributed to the rising demand for better healthcare services, rapid development in the healthcare infrastructure of emerging markets, and the growing government initiatives on preventive care methods.
A breakdown of the primary participants for the in vitro diagnostics market referred to for this report is provided below:
•By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
•By Designation: C-level–35%, Director Level–25%, and Others–40%
•By Region: North America–45%, Europe–30%, Asia Pacific–20%, Latin America – 3%, Middle East & Africa – 2%
The prominent players in the global in vitro diagnostics market are Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc (US), Becton, Dickinson and Company (BD, US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Quidel Corporation (US), bioMérieux SA (France), Agilent Technologies, Inc. (US), Chembio Diagnostics, Inc. (US), DiaSorin S.p.A (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Devyser (Sweden), PerkinElmer Inc. (US), Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), and Caris Life Sciences Inc. (US).
Research Coverage
The report analyzes the market for various in vitro diagnostics products & services and their adoption pattern. It aims at estimating the market size and future growth potential of the in vitro diagnostics market and different segments such as by technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, services, and recent developments.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers:
•Market Penetration: Comprehensive information on the service portfolios offered by the top players in the global in vitro diagnostics market.
•Service Development/Innovation: Detailed insights on the upcoming trend, and service launches in the global in vitro diagnostics market.
•Market Development: Comprehensive information on the lucrative emerging regions by product & services, technology, application, end users, and region.
•Market Diversification: Exhaustive information about new products & services, growing geographies, and recent developments in the global in vitro diagnostics market.
•Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global in vitro diagnostics market.
1INTRODUCTION43
1.1STUDY OBJECTIVES43
1.2MARKET DEFINITION43
1.2.1INCLUSIONS & EXCLUSIONS44
1.2.2MARKET SEGMENTATION45
FIGURE 1IN VITRO DIAGNOSTICS MARKET SEGMENTATION45
1.2.3YEARS CONSIDERED46
1.3CURRENCY CONSIDERED46
TABLE 1EXCHANGE RATES UTILIZED FOR CONVERSION TO USD46
1.4STAKEHOLDERS47
1.5SUMMARY OF CHANGES47
2RESEARCH METHODOLOGY48
2.1RESEARCH APPROACH48
FIGURE 2RESEARCH DESIGN48
2.1.1SECONDARY RESEARCH48
2.1.1.1Key data from secondary sources49
2.1.2PRIMARY RESEARCH50
2.1.2.1Primary sources50
2.1.2.2Key data from primary sources51
2.1.2.3Key industry insights51
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS52
FIGURE 4BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION52
FIGURE 5BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION53
2.2MARKET SIZE ESTIMATION53
FIGURE 6MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021)54
FIGURE 7REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2021)54
FIGURE 8SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS MARKET (2021)55
FIGURE 9IVD MARKET: TOP-DOWN APPROACH56
FIGURE 10CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE
IVD INDUSTRY (2022–2027)57
FIGURE 11CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET57
2.3DATA TRIANGULATION APPROACH59
FIGURE 12DATA TRIANGULATION METHODOLOGY59
2.4MARKET SHARE ESTIMATION60
2.5STUDY ASSUMPTIONS60
2.6LIMITATIONS60
2.6.1METHODOLOGY-RELATED LIMITATIONS60
2.6.2SCOPE-RELATED LIMITATIONS60
2.7RISK ASSESSMENT61
TABLE 2RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET61
3EXECUTIVE SUMMARY62
FIGURE 13IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION)62
FIGURE 14IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022 VS. 2027 (USD MILLION)63
FIGURE 15IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION)63
FIGURE 16IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION)64
FIGURE 17GEOGRAPHIC SNAPSHOT OF IVD MARKET65
4PREMIUM INSIGHTS66
4.1IN VITRO DIAGNOSTICS MARKET OVERVIEW66
FIGURE 18RISING INCIDENCE OF INFECTIOUS DISEASES AND GROWING ADOPTION OF TECHNOLOGICALLY ADVANCED ANALYZERS TO DRIVE MARKET66
4.2ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021)67
FIGURE 19REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 202167
4.3IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES68
FIGURE 20CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD68
4.4IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX68
FIGURE 21ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD68
4.5IN VITRO DIAGNOSTICS MARKET: EMERGING VS. DEVELOPED MARKETS69
FIGURE 22EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD69
5MARKET OVERVIEW70
5.1INTRODUCTION70
5.2MARKET DYNAMICS70
FIGURE 23IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES70
5.2.1DRIVERS71
5.2.1.1Increasing geriatric population and subsequent rise in chronic & infectious diseases71
TABLE 3ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019–2050)71
5.2.1.2Gradual shift from centralized testing to point-of-care testing72
5.2.1.3Growing awareness of early disease diagnosis in emerging economies72
5.2.1.4Emergence of rapid PoC technologies and rising adoption of automated analyzers73
TABLE 4IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES (2020−2022)73
5.2.2RESTRAINTS74
5.2.2.1Unfavorable reimbursement scenario74
5.2.3OPPORTUNITIES74
5.2.3.1Introduction of disease-specific biomarkers and tests74
TABLE 5APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE75
5.2.3.2Growing significance of companion diagnostics75
5.2.3.3Growth opportunities in emerging markets76
TABLE 6RECENT DEVELOPMENTS IN EMERGING MARKETS76
5.2.4CHALLENGES77
5.2.4.1Stringent regulatory & legal guidelines77
FIGURE 24IVDR: KEY AREAS OF IMPACT77
5.2.4.2Operational barriers78
TABLE 7IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES78
5.3INDUSTRY TRENDS79
5.3.1AUTOMATION OF CLINICAL LABORATORY TECHNIQUES79
5.3.2MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING79
5.3.3RISING NUMBER OF REAGENT RENTAL AGREEMENTS80
5.3.4REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS80
FIGURE 25REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS80
5.4PORTER’S FIVE FORCES ANALYSIS81
TABLE 8PORTER’S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET81
5.4.1INTENSITY OF COMPETITIVE RIVALRY81
5.4.2BARGAINING POWER OF SUPPLIERS81
5.4.3BARGAINING POWER OF BUYERS81
5.4.4THREAT OF NEW ENTRANTS81
5.4.5THREAT FROM SUBSTITUTES82
5.5REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS82
TABLE 9LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS82
5.6REGULATORY ANALYSIS83
5.6.1NORTH AMERICA83
5.6.1.1US83
TABLE 10US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES83
FIGURE 26US: REGULATORY PROCESS FOR IVD DEVICES84
5.6.1.2Canada85
FIGURE 27CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA85
5.6.2EUROPE85
TABLE 11EUROPE: CLASSIFICATION OF IVD DEVICES86
FIGURE 28EUROPE: IVDR TIMELINE86
5.6.3ASIA PACIFIC87
5.6.3.1Japan87
FIGURE 29REGULATORY PROCESS FOR IVD DEVICES IN JAPAN87
TABLE 12JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN88
TABLE 13JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS88
5.6.3.2China88
TABLE 14CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS88
5.6.3.3India89
FIGURE 30INDIA: REGULATORY PROCESS FOR IVD DEVICES89
5.6.3.4South Korea89
TABLE 15SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS89
5.6.3.5Indonesia90
TABLE 16INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES90
5.6.4RUSSIA90
TABLE 17RUSSIA: CLASSIFICATION OF IVD DEVICES91
5.6.5MIDDLE EAST & AFRICA91
5.6.5.1Saudi Arabia91
TABLE 18SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS91
5.6.5.2Africa91
5.6.6LATIN AMERICA92
5.6.6.1Mexico92
FIGURE 31MEXICO: REGULATORY PROCESS FOR IVD DEVICES92
TABLE 19MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS93
5.6.6.2Brazil93
5.7KEY CONFERENCES & EVENTS IN 202394
TABLE 20IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS94
5.8PATENT ANALYSIS95
5.8.1INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS95
FIGURE 32TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011–DECEMBER 2022)95
FIGURE 33TOP APPLICANT JURISDICTIONS FOR IVD PATENTS
(JANUARY 20211-DECEMBER 2022)96
5.8.2PATENT PUBLICATION TRENDS FOR IN VITRO DIAGNOSTICS MARKET96
FIGURE 34PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET
(JANUARY 2011–DECEMBER 2022)96
TABLE 21LIST OF PATENTS/PATENT APPLICATIONS IN IVD MARKET, 2021–202297
5.9TRADE ANALYSIS98
5.9.1TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS98
TABLE 22IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (USD MILLION)98
TABLE 23EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (TONS)98
5.10ECOSYSTEM ANALYSIS98
FIGURE 35ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET99
5.10.1IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM99
5.11VALUE CHAIN ANALYSIS100
FIGURE 36VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET100
5.12SUPPLY CHAIN ANALYSIS101
FIGURE 37SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET101
5.13PRICING ANALYSIS102
5.13.1INDICATIVE AVERAGE SELLING PRICE (USD) REGION-WISE: REAGENTS & KITS102
5.13.2AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS102
5.13.3AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS102
5.13.4AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS103
5.14TECHNOLOGY ANALYSIS104
5.14.1KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET104
5.14.2ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET105
5.15CASE STUDY106
FIGURE 38CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA106
5.16KEY STAKEHOLDERS & BUYING CRITERIA107
5.16.1KEY STAKEHOLDERS IN BUYING PROCESS107
FIGURE 39INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS107
TABLE 24INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS (%)107
5.16.2BUYING CRITERIA108
FIGURE 40KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS108
TABLE 25KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS108
5.17IMPACT OF RECESSION ON IVD MARKET (2021–2024)108
5.18IMPACT OF IN VITRO DIAGNOSTIC REGULATIONS (IVDR) ON LABORATORY TESTING109
6IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE111
6.1INTRODUCTION112
TABLE 26IN VITRO DIAGNOSTIC MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION)112
6.2REAGENTS & KITS112
6.2.1GROWING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET112
TABLE 27IVD MARKET FOR REAGENTS & KITS, BY COUNTRY,
2020–2027 (USD MILLION)114
6.3INSTRUMENTS114
TABLE 28KEY INSTRUMENTS AVAILABLE IN IVD MARKET115
TABLE 29IVD MARKET FOR INSTRUMENTS, BY TYPE, 2020–2027 (USD MILLION)116
TABLE 30IVD MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)116
6.3.1FULLY AUTOMATED INSTRUMENTS117
6.3.1.1Rising availability of technologically advanced analyzers to drive market117
TABLE 31IVD MARKET FOR FULLY AUTOMATED INSTRUMENTS, BY COUNTRY,
2020–2027 (USD MILLION)118
6.3.2SEMI-AUTOMATED INSTRUMENTS118
6.3.2.1Compact design and cost-effectiveness over automated analyzers to support market growth118
TABLE 32IVD MARKET FOR SEMIAUTOMATED INSTRUMENTS, BY COUNTRY,
2020–2027 (USD MILLION)119
6.3.3OTHER INSTRUMENTS119
TABLE 33IVD MARKET FOR OTHER INSTRUMENTS, BY COUNTRY,
2020–2027 (USD MILLION)120
6.4DATA MANAGEMENT SOFTWARE120
6.4.1GROWING ADOPTION OF AUTOMATED ANALYZERS AND RISING NEED FOR EFFECTIVE DATA MANAGEMENT TO DRIVE MARKET120
TABLE 34KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN IVD MARKET121
TABLE 35IVD MARKET FOR DATA MANAGEMENT SOFTWARE, BY COUNTRY,
2020–2027 (USD MILLION)122
6.5SERVICES122
6.5.1RISING NEED TO ENSURE EFFECTIVE UTILISATION OF IVD PRODUCTS TO SUPPORT MARKET GROWTH122
TABLE 36IVD MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)123
7IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY124
7.1INTRODUCTION125
TABLE 37IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION)125
7.2IMMUNOASSAY/IMMUNOCHEMISTRY125
TABLE 38KEY IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE IN IVD MARKET126
TABLE 39IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY,
BY TYPE, 2020–2027 (USD MILLION)127
TABLE 40IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY,
BY COUNTRY, 2020–2027 (USD MILLION)127
7.2.1ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)128
TABLE 41KEY ELISA ANALYZERS AVAILABLE IN IVD MARKET128
TABLE 42IVD MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)129
TABLE 43IVD MARKET FOR ELISA, BY COUNTRY, 2020–2027 (USD MILLION)130
7.2.1.1Chemiluminescence Immunoassays130
7.2.1.1.1Rising technological advancements and continuous product innovations to drive segment growth130
TABLE 44KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET131
TABLE 45IVD MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)132
7.2.1.2Fluorescence Immunoassays132
7.2.1.2.1Rising demand for low-cost fluorescent dyes to drive segment growth132
TABLE 46KEY FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET133
TABLE 47IVD MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY,
2020–2027 (USD MILLION)134
7.2.1.3Colorimetric Immunoassays134
7.2.1.3.1High specificity and easy coagulation to antibodies to drive segment growth134
TABLE 48KEY COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET135
TABLE 49IVD MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY,
2020–2027 (USD MILLION)135
7.2.2RADIOIMMUNOASSAYS136
7.2.2.1Usage of RIAs in cancer detection, blood screening, and drug discovery to drive market136
TABLE 50IVD MARKET FOR RADIOIMMUNOASSAYS, BY COUNTRY,
2020–2027 (USD MILLION)136
7.2.3RAPID TESTS137
7.2.3.1Rising usage of rapid tests for emergency care to drive market137
TABLE 51KEY RAPID TESTS AVAILABLE IN IVD MARKET137
TABLE 52IVD MARKET FOR RAPID TESTS, BY COUNTRY, 2020–2027 (USD MILLION)138
7.2.4WESTERN BLOTTING138
7.2.4.1Widely accepted technique for result validation to support market growth138
TABLE 53KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN IVD MARKET139
TABLE 54IVD MARKET FOR WESTERN BLOTTING, BY COUNTRY,
2020–2027 (USD MILLION)139
7.2.5ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)140
7.2.5.1High sensitivity and adaptability of technology to fuel market adoption140
TABLE 55IVD MARKET FOR ELISPOT ASSAYS, BY COUNTRY,
2020–2027 (USD MILLION)140
7.3CLINICAL CHEMISTRY141
TABLE 56CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES141
TABLE 57CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES142
TABLE 58KEY BLOOD GAS ANALYZERS AVAILABLE IN IVD MARKET143
TABLE 59IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE,
2020–2027 (USD MILLION)144
TABLE 60CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)144
7.3.1BASIC METABOLIC PANELS145
7.3.1.1Set of blood tests performed to ascertain common acute conditions145
TABLE 61IVD MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY,
2020–2027 (USD MILLION)145
7.3.2LIVER PANELS146
7.3.2.1Panels used to identify and monitor liver diseases & injuries146
TABLE 62IVD MARKET FOR LIVER PANELS, BY COUNTRY, 2020–2027 (USD MILLION)146
7.3.3RENAL PROFILES147
7.3.3.1Panels used to monitor cytokines & chemokines in urine147
TABLE 63IVD MARKET FOR RENAL PROFILES, BY COUNTRY,
2020–2027 (USD MILLION)147
7.3.4LIPID PROFILES148
7.3.4.1Lipid panel testing determines total cholesterol and risk status for CVD148
TABLE 64IVD MARKET FOR LIPID PROFILES, BY COUNTRY,
2020–2027 (USD MILLION)148
7.3.5THYROID FUNCTION PANELS149
7.3.5.1Tests performed to determine TSH and thyroglobulin149
TABLE 65IVD MARKET FOR THYROID FUNCTION PANELS, BY COUNTRY,
2020–2027 (USD MILLION)149
7.3.6ELECTROLYTE PANELS150
7.3.6.1Prescribed for symptoms such as edema, nausea, and cardiac arrhythmia150
TABLE 66IVD MARKET FOR ELECTROLYTE PANELS, BY COUNTRY,
2020–2027 (USD MILLION)150
7.3.7SPECIALTY CHEMICAL TESTS151
7.3.7.1Test profile includes immunosuppressant drug monitoring and drugs of abuse151
TABLE 67IVD MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY,
2020–2027 (USD MILLION)151
7.4MOLECULAR DIAGNOSTICS152
TABLE 68KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN IVD MARKET152
TABLE 69IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE,
2020–2027 (USD MILLION)153
TABLE 70IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY,
2020–2027 (USD MILLION)154
7.4.1POLYMERASE CHAIN REACTION (PCR)154
7.4.1.1Rising prevalence of infectious & viral diseases to drive market154
TABLE 71KEY PCR INSTRUMENTS AVAILABLE IN IVD MARKET155
TABLE 72IVD MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY,
2020–2027 (USD MILLION)156
7.4.2ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)156
7.4.2.1Growing popularity of INAAT and NAAT for infectious disease diagnostics to support market growth156
TABLE 73IVD MARKET FOR INAAT, BY COUNTRY, 2020–2027 (USD MILLION)157
7.4.3HYBRIDIZATION157
7.4.3.1Advanced hybridization & automation of data collection techniques to support market growth157
TABLE 74IVD MARKET FOR HYBRIDIZATION, BY COUNTRY, 2020–2027 (USD MILLION)158
7.4.4DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)158
7.4.4.1Rising demand for personalized medicine to support market growth158
TABLE 75KEY NGS INSTRUMENTS AVAILABLE IN IVD MARKET159
TABLE 76IVD MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY,
2020–2027 (USD MILLION)160
7.4.5MICROARRAYS160
7.4.5.1High throughput & resolution capabilities to drive market for protein expression profiling160
TABLE 77IVD MARKET FOR MICROARRAYS, BY COUNTRY, 2020–2027 (USD MILLION)161
7.4.6OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES162
TABLE 78IVD MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES,
BY COUNTRY, 2020–2027 (USD MILLION)162
7.5HEMATOLOGY163
7.5.1INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS TO DRIVE MARKET163
TABLE 79KEY HEMATOLOGY ANALYZERS AVAILABLE IN IVD MARKET163
TABLE 80IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)164
7.6MICROBIOLOGY165
7.6.1RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET165
TABLE 81KEY MICROBIOLOGY INSTRUMENTS AVAILABLE IN IVD MARKET165
TABLE 82IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)166
7.7COAGULATION & HEMOSTASIS167
7.7.1GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET167
TABLE 83KEY COAGULATION ANALYZERS AVAILABLE IN IVD MARKET167
TABLE 84KEY POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE IN IVD MARKET168
TABLE 85IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY,
2020–2027 (USD MILLION)169
7.8URINALYSIS169
7.8.1RISING PREVALENCE OF KIDNEY DISORDERS AND UTIS TO DRIVE MARKET169
TABLE 86KEY URINALYSIS INSTRUMENTS AVAILABLE IN IVD MARKET170
TABLE 87IVD MARKET FOR URINALYSIS, BY COUNTRY, 2020–2027 (USD MILLION)171
7.9OTHER TECHNOLOGIES171
TABLE 88KEY BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN IVD MARKET172
TABLE 89TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE IN IVD MARKET172
TABLE 90IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,
2020–2027 (USD MILLION)173
8IN VITRO DIAGNOSTICS MARKET, BY APPLICATION174
8.1INTRODUCTION175
TABLE 91IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION)175
8.2INFECTIOUS DISEASES175
8.2.1INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE ADOPTION OF IVD PRODUCTS175
TABLE 92IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2020–2027 (USD MILLION)176
8.3DIABETES177
8.3.1RISING PREVALENCE OF DIABETES TO DRIVE ADOPTION OF GLUCOSE MONITORING DEVICES177
TABLE 93COUNTRIES WITH A DIABETIC PATIENT POPULATION,
2021 VS. 2045 (MILLION)177
TABLE 94IVD MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION)178
8.4ONCOLOGY178
8.4.1RISING INITIATIVES FOR EARLY DETECTION OF CANCER TO DRIVE MARKET178
TABLE 95IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)179
8.5CARDIOLOGY180
8.5.1INCREASING USE OF IMMUNOASSAYS IN DETECTION OF CVD TO DRIVE MARKET180
TABLE 96IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)181
8.6DRUG TESTING/PHARMACOGENOMICS181
8.6.1INCREASING USE OF TOXICOLOGY TESTING FOR ILLICIT DRUGS TO DRIVE MARKET181
TABLE 97IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY, 2020–2027 (USD MILLION)182
8.7HIV/AIDS182
8.7.1INCREASING USAGE OF REAL-TIME PCR TESTS FOR HIV DETECTION TO DRIVE MARKET182
TABLE 98IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2020–2027 (USD MILLION)183
8.8AUTOIMMUNE DISEASES183
8.8.1GROWING DEMAND FOR PORTABLE POC DIAGNOSTIC DEVICES TO DRIVE MARKET183
TABLE 99IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY,
2020–2027 (USD MILLION)184
8.9NEPHROLOGY185
8.9.1INCREASING USE OF BIOMARKERS FOR CKD TO SUPPORT MARKET GROWTH185
TABLE 100IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)186
8.10OTHER APPLICATIONS186
TABLE 101IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION)187
9IN VITRO DIAGNOSTICS MARKET, BY END USER188
9.1INTRODUCTION189
TABLE 102IN-VITRO DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)189
9.2HOSPITAL LABORATORIES189
9.2.1RISING NUMBER OF HOSPITALIZATIONS DUE TO INCREASING INFECTIOUS DISEASES TO DRIVE MARKET189
TABLE 103IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY,
2020–2027 (USD MILLION)191
9.3CLINICAL LABORATORIES191
TABLE 104IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)192
TABLE 105IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)192
9.3.1LARGE REFERENCE LABORATORIES193
9.3.1.1Capability to conduct specific tests such as LDTs with advanced diagnostic tools to drive segment growth193
TABLE 106LARGE REFERENCE LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)193
9.3.2MEDIUM-SIZED LABORATORIES194
9.3.2.1Increasing adoption of automated instruments to drive growth of this segment194
TABLE 107MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)194
9.3.3SMALL LABORATORIES195
9.3.3.1Adoption of point-of-care devices to support segment growth195
TABLE 108SMALL LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)195
9.4POINT-OF-CARE TESTING CENTERS196
9.4.1RISING DEMAND FOR RAPID TESTING AND AVAILABILITY OF INNOVATIVE POINT-OF-CARE IVD PRODUCTS TO DRIVE MARKET196
TABLE 109IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2020–2027 (USD MILLION)197
9.5PATIENTS197
9.5.1USE OF CONVENIENT SELF-TEST KITS TO DRIVE MARKET197
TABLE 110IVD MARKET FOR PATIENTS, BY COUNTRY, 2020–2027 (USD MILLION)198
9.6ACADEMIC INSTITUTES199
9.6.1RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH199
TABLE 111IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)199
9.7OTHER END USERS200
TABLE 112IVD MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)201
10IN VITRO DIAGNOSTICS MARKET, BY REGION202
10.1INTRODUCTION203
FIGURE 41IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT (2021)203
TABLE 113IN VITRO DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION)204
10.2NORTH AMERICA204
FIGURE 42NORTH AMERICA: IVD MARKET SNAPSHOT205
TABLE 114NORTH AMERICA: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)205
TABLE 115NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)206
TABLE 116NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)206
TABLE 117NORTH AMERICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)207
TABLE 118NORTH AMERICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)207
TABLE 119NORTH AMERICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)208
TABLE 120NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)208
10.2.1US208
10.2.1.1Established reimbursement framework and favorable policies for IVD providers to drive market208
TABLE 121US: MACROECONOMIC INDICATORS210
TABLE 122US: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)210
TABLE 123US: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)210
TABLE 124US: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)211
TABLE 125US: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)211
TABLE 126US: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)212
TABLE 127US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)212
10.2.2CANADA212
10.2.2.1Rising government initiatives & funding for early disease diagnosis to drive market212
TABLE 128CANADA: ESTIMATED PREVALENCE OF DIABETES213
TABLE 129CANADA: MACROECONOMIC INDICATORS214
TABLE 130CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)214
TABLE 131CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)215
TABLE 132CANADA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)215
TABLE 133CANADA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)216
TABLE 134CANADA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)216
TABLE 135CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)217
10.3EUROPE217
TABLE 136EUROPE: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)218
TABLE 137EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)218
TABLE 138EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)218
TABLE 139EUROPE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)219
TABLE 140EUROPE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)219
TABLE 141EUROPE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)220
TABLE 142EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)220
10.3.1GERMANY220
10.3.1.1Growing investments in clinical diagnostics research to drive market220
TABLE 143GERMANY: MACROECONOMIC INDICATORS221
TABLE 144GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)221
TABLE 145GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)222
TABLE 146GERMANY: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)222
TABLE 147GERMANY: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)223
TABLE 148GERMANY: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)223
TABLE 149GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)224
10.3.2FRANCE224
10.3.2.1High healthcare expenditure and rising investments in genomic medicine to drive market224
TABLE 150FRANCE: MACROECONOMIC INDICATORS225
TABLE 151FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)225
TABLE 152FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)225
TABLE 153FRANCE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)226
TABLE 154FRANCE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)226
TABLE 155FRANCE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)227
TABLE 156FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)227
10.3.3UK227
10.3.3.1Rising adoption of genome-based testing and increasing accessibility to IVD tests to drive market227
TABLE 157UK: MACROECONOMIC INDICATORS228
TABLE 158UK: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)229
TABLE 159UK: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)229
TABLE 160UK: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)230
TABLE 161UK: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)230
TABLE 162UK: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)231
TABLE 163UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)231
10.3.4ITALY231
10.3.4.1Growing geriatric population and subsequent rise in chronic conditions to support market growth231
TABLE 164ITALY: MACROECONOMIC INDICATORS232
TABLE 165ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)233
TABLE 166ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)233
TABLE 167ITALY: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)233
TABLE 168ITALY: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)234
TABLE 169ITALY: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)234
TABLE 170ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)235
10.3.5SPAIN235
10.3.5.1Rising adoption of technologically advanced immunoassay systems to drive market235
TABLE 171SPAIN: MACROECONOMIC INDICATORS236
TABLE 172SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)236
TABLE 173SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)236
TABLE 174SPAIN: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)237
TABLE 175SPAIN: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)237
TABLE 176SPAIN: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)238
TABLE 177SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)238
10.3.6RUSSIA238
10.3.6.1Rising incidence of non-communicable diseases and government support for medical services to support market growth238
TABLE 178RUSSIA: MACROECONOMIC INDICATORS239
TABLE 179RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)239
TABLE 180RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)240
TABLE 181RUSSIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)240
TABLE 182RUSSIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)241
TABLE 183RUSSIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)241
TABLE 184RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)242
10.3.7REST OF EUROPE242
TABLE 185REST OF EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)242
TABLE 186REST OF EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)243
TABLE 187REST OF EUROPE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)243
TABLE 188REST OF EUROPE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)244
TABLE 189REST OF EUROPE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)244
TABLE 190REST OF EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)245
10.4ASIA PACIFIC245
FIGURE 43ASIA PACIFIC: IVD MARKET SNAPSHOT246
TABLE 191ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)247
TABLE 192ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)247
TABLE 193ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)247
TABLE 194ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)248
TABLE 195ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)248
TABLE 196ASIA PACIFIC: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)249
TABLE 197ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)249
10.4.1JAPAN249
10.4.1.1Universal healthcare reimbursement policy and research investments for immunoassays to support market growth249
TABLE 198JAPAN: MACROECONOMIC INDICATORS250
TABLE 199JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)251
TABLE 200JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)251
TABLE 201JAPAN: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION))251
TABLE 202JAPAN: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)252
TABLE 203JAPAN: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)252
TABLE 204JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)253
10.4.2CHINA253
10.4.2.1Increasing awareness of preventive care to drive market for advanced & rapid testing platforms253
TABLE 205CHINA: MACROECONOMIC INDICATORS254
TABLE 206CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)254
TABLE 207CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)254
TABLE 208CHINA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)255
TABLE 209CHINA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)255
TABLE 210CHINA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)256
TABLE 211CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)256
10.4.3INDIA256
10.4.3.1Rising incidence of diabetes and cancer to fuel market growth for IVD products256
TABLE 212INDIA: MACROECONOMIC INDICATORS257
TABLE 213INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)258
TABLE 214INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)258
TABLE 215INDIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)258
TABLE 216INDIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)259
TABLE 217INDIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)259
TABLE 218INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)260
10.4.4SOUTH KOREA260
10.4.4.1Rising healthcare spending for innovative IVD technologies to support market growth260
TABLE 219SOUTH KOREA: MACROECONOMIC INDICATORS261
TABLE 220SOUTH KOREA: IVD MA
Related Report
